Skip To Main Content
Barbara Dreta on Muck Rack

Barbara Dreta

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

|
By Jan Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel, Lucas Mix, Andreas Riedel, Robin Sanderson, Urban Novak, Ron Ram, David Beauvais, Daniela Taurino, Robin Noel, Lucía López Corral, Almudena Cabero, Ralph Wäsch, Malte von Bonin, Peter Vandenberghe, Olaf Penack, Björn Chapuy, Avichai Shimoni, Barbara Dreta, Ulf Schnetzke, Eugenio Galli, Tobias Holderried, Claudia Lengerke, Norbert Schmitz, Wolfgang Andreas Bethge, Fizza Imran, Maria-Luisa Schubert, Maxime Delforge
| Nature Verified
CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) is standard-of-care second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) [1,2,3]. Bispecific antibodies (BSA) and polatuzumab vedotin (pola) are increasingly used prior to CAR-T, but the impact of such exposure, particularly before leukapheresis, when therapies may affect T-cell collection and fitness, remains unclear [4,5,6,7].
Open in Who Shared Issue with article?

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)

|
By Josip Batinić, Karla Mišura Jakobac, Barbara Dreta, Delfa Radić Krišto
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 2 articles